← All trials
NCT03164291
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 1984
- Primary completion
- Sep 1, 2006
- Completion date
- May 18, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 170
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of Texas, TylerLead sponsor
- PfizerCollaborator
- University of Texas, TylerOverall official - principal investigator
- University of Texas, TylerReponsible party - principal investigator
- University of Texas at HoustonStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.